Company intelligence / Profile preview

Hedgehog, Inc.

Seoul, South Korea

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Hedgehog is developing first-in-class and best-in-class monoclonal antibodies and small molecule inhibitors targeting the Hedgehog signaling pathway to treat various solid cancers. Their lead programs (HH101, HH102, HH103, HH201) are in discovery or preclinical stages, with a focus on overcoming drug resistance and minimizing side effects.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodySmall molecule drug
Industry: Biotech

Drug pipeline

3 assets

HH101

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Hedgehog, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hedgehog, Inc..

Explore the full profile